Breaking News

AGC Biologics, MacroGenics Ink Commercial Supply Pact

To manufacture MacroGenics' margetuximab, a clinical-stage immune-optimized monoclonal antibody

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AGC Biologics has entered into a commercial supply agreement with MacroGenics for the manufacture of margetuximab, a clinical-stage, novel immune-optimized monoclonal antibody. MacroGenics is a clinical-stage biopharma company developing monoclonal antibody-based therapeutics for the treatment of cancer.   AGC Biologics has provided development and validation services for margetuximab since 2014, and plans to implement a transition to commercial supply services.   Margetuximab is an investig...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters